Join us 22 October
8am PDT | 11am EDT | 4pm BST | 5pm CEST
The complex structure-activity relationships between peptide sequence, 3D conformation, and diverse biological activities make peptide drug discovery extremely challenging. However, emerging machine learning methods show promise in addressing these challenges.
In this webinar, Dr Samar Mahmoud (Principal Scientist, Optibrium) and Dr Matt Segall (CEO, Optibrium), will describe a unique deep learning approach to peptide bioactivity and property prediction in drug discovery. Dr Dan Sindhikara (Principal Scientist, MSD), who was a scientific collaborator, will be present during the Q&A section of the webinar.
In this first public presentation of the results of Optibrium and MSD’s scientific collaboration, we will show how deep learning transformed the accuracy of prediction of bioactivities and other properties and how the results can be used to guide experimental prioritisation.
If you want to be on the cutting-edge of peptide drug discovery, this webinar is not to be missed.
